Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
AMN Healthcare Services Inc stock logo
AMN
AMN Healthcare Services
$20.89
-0.7%
$20.97
$17.45
$70.07
$799.39M0.19894,287 shs1.60 million shs
MSPR
MSP Recovery
$1.21
-4.0%
$1.60
$1.10
$13.50
$9.97M-2.4945,864 shs39,038 shs
Perrigo Company plc stock logo
PRGO
Perrigo
$26.55
-0.1%
$26.31
$23.14
$30.93
$3.65B0.461.46 million shs952,191 shs
Prometheus Biosciences, Inc. stock logo
RXDX
Prometheus Biosciences
$199.92
$198.62
$23.27
$199.98
$9.56B-0.49913,102 shsN/A
The 10 Best AI Stocks to Own in 2025 Cover

Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
AMN Healthcare Services Inc stock logo
AMN
AMN Healthcare Services
-0.68%-4.76%-0.94%-11.28%-61.00%
MSPR
MSP Recovery
-3.97%-4.72%-8.33%-12.32%+120,999,900.00%
Perrigo Company plc stock logo
PRGO
Perrigo
-0.24%+0.14%-1.90%-5.38%+3.15%
Prometheus Biosciences, Inc. stock logo
RXDX
Prometheus Biosciences
0.00%0.00%0.00%0.00%0.00%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
AMN Healthcare Services Inc stock logo
AMN
AMN Healthcare Services
3.9886 of 5 stars
3.11.00.04.31.41.71.9
MSPR
MSP Recovery
N/AN/AN/AN/AN/AN/AN/AN/A
Perrigo Company plc stock logo
PRGO
Perrigo
4.8265 of 5 stars
2.15.04.23.52.71.72.5
Prometheus Biosciences, Inc. stock logo
RXDX
Prometheus Biosciences
N/AN/AN/AN/AN/AN/AN/AN/A
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
AMN Healthcare Services Inc stock logo
AMN
AMN Healthcare Services
2.25
Hold$32.0853.57% Upside
MSPR
MSP Recovery
0.00
N/AN/AN/A
Perrigo Company plc stock logo
PRGO
Perrigo
2.25
Hold$33.0024.28% Upside
Prometheus Biosciences, Inc. stock logo
RXDX
Prometheus Biosciences
0.00
N/AN/AN/A

Current Analyst Ratings Breakdown

Latest AMN, MSPR, PRGO, and RXDX Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
5/13/2025
AMN Healthcare Services Inc stock logo
AMN
AMN Healthcare Services
UBS Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetNeutral ➝ Neutral$30.00 ➝ $25.50
4/15/2025
AMN Healthcare Services Inc stock logo
AMN
AMN Healthcare Services
Truist Financial
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$40.00 ➝ $25.00
(Data available from 6/28/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
AMN Healthcare Services Inc stock logo
AMN
AMN Healthcare Services
$2.98B0.27$13.74 per share1.52$18.56 per share1.13
MSPR
MSP Recovery
$18.25M0.55$60.50 per share0.02($17.97) per share-0.07
Perrigo Company plc stock logo
PRGO
Perrigo
$4.37B0.83$5.05 per share5.26$31.66 per share0.84
Prometheus Biosciences, Inc. stock logo
RXDX
Prometheus Biosciences
$6.81M1,403.55N/AN/A$16.12 per share12.40
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
AMN Healthcare Services Inc stock logo
AMN
AMN Healthcare Services
-$146.98M-$4.33N/A8.63N/A-5.80%13.39%4.17%8/6/2025 (Estimated)
MSPR
MSP Recovery
-$360.50M-$142.50N/AN/A-3,540.07%-326.80%-48.26%N/A
Perrigo Company plc stock logo
PRGO
Perrigo
-$171.80M-$1.31N/A8.68N/A-4.16%8.93%3.87%8/1/2025 (Estimated)
Prometheus Biosciences, Inc. stock logo
RXDX
Prometheus Biosciences
-$141.75M-$3.52N/AN/AN/A-3,768.76%-33.50%-29.59%N/A

Latest AMN, MSPR, PRGO, and RXDX Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/15/2025Q1 2025
MSPR
MSP Recovery
N/A-$33.70N/A-$33.70N/A$0.84 million
5/8/2025Q1 2025
AMN Healthcare Services Inc stock logo
AMN
AMN Healthcare Services
$0.19$0.45+$0.26-$0.03$670.08 million$689.53 million
5/7/2025Q1 2025
Perrigo Company plc stock logo
PRGO
Perrigo
$0.56$0.60+$0.04-$0.05$1.09 billion$1.04 billion
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
AMN Healthcare Services Inc stock logo
AMN
AMN Healthcare Services
N/AN/AN/AN/AN/A
MSPR
MSP Recovery
N/AN/AN/AN/AN/A
Perrigo Company plc stock logo
PRGO
Perrigo
$1.164.37%N/AN/A 23 Years
Prometheus Biosciences, Inc. stock logo
RXDX
Prometheus Biosciences
N/AN/AN/AN/AN/A

Latest AMN, MSPR, PRGO, and RXDX Dividends

AnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
4/30/2025
Perrigo Company plc stock logo
PRGO
Perrigo
quarterly$0.294.55%5/30/20255/30/20256/17/2025
(Data available from 1/1/2013 forward)
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
AMN Healthcare Services Inc stock logo
AMN
AMN Healthcare Services
1.39
1.08
1.08
MSPR
MSP Recovery
0.85
0.02
0.02
Perrigo Company plc stock logo
PRGO
Perrigo
0.82
2.36
1.28
Prometheus Biosciences, Inc. stock logo
RXDX
Prometheus Biosciences
0.04
37.56
37.56

Institutional Ownership

CompanyInstitutional Ownership
AMN Healthcare Services Inc stock logo
AMN
AMN Healthcare Services
99.23%
MSPR
MSP Recovery
3.77%
Perrigo Company plc stock logo
PRGO
Perrigo
95.91%
Prometheus Biosciences, Inc. stock logo
RXDX
Prometheus Biosciences
92.66%

Insider Ownership

CompanyInsider Ownership
AMN Healthcare Services Inc stock logo
AMN
AMN Healthcare Services
0.93%
MSPR
MSP Recovery
75.17%
Perrigo Company plc stock logo
PRGO
Perrigo
0.70%
Prometheus Biosciences, Inc. stock logo
RXDX
Prometheus Biosciences
3.40%
CompanyEmployeesShares OutstandingFree FloatOptionable
AMN Healthcare Services Inc stock logo
AMN
AMN Healthcare Services
2,96838.28 million37.93 millionOptionable
MSPR
MSP Recovery
38.24 million2.05 millionN/A
Perrigo Company plc stock logo
PRGO
Perrigo
8,379137.48 million136.52 millionOptionable
Prometheus Biosciences, Inc. stock logo
RXDX
Prometheus Biosciences
9747.81 million46.19 millionNot Optionable

Recent News About These Companies

Prometheus Biosciences (NASDAQ: RXDX)

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All Headlines
AMN Healthcare Services stock logo

AMN Healthcare Services NYSE:AMN

$20.89 -0.15 (-0.71%)
Closing price 06/27/2025 03:59 PM Eastern
Extended Trading
$20.88 -0.02 (-0.08%)
As of 06/27/2025 04:34 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

AMN Healthcare Services, Inc. provides healthcare workforce solutions and staffing services to healthcare facilities in the United States. It operates through three segments: Nurse and Allied Solutions, Physician and Leadership Solutions, and Technology and Workforce Solutions. The Nurse and Allied Solutions segment offers travel nurse staffing, labor disruption staffing, local staffing, international nurse and allied permanent placement, and allied staffing solutions. The Physician and Leadership Solutions segment provides locum tenens staffing, healthcare interim leadership staffing, executive search, and physician permanent placement solutions. The Technology and Workforce Solutions segment offers language services, vendor management systems, workforce optimization, and outsourced solutions. The company also provides allied health professionals, such as physical therapists, respiratory therapists, occupational therapists, medical and radiology technologists, lab technicians, speech pathologists, rehabilitation assistants, and pharmacists. It offers its services under the brands, including AMN Healthcare, Nursefinders, HealthSource Global Staffing, O'Grady Peyton International, Connetics, Medical Search International, DRW Healthcare Staffing, and B.E. Smith. AMN Healthcare Services, Inc. was founded in 1985 and is headquartered in Dallas, Texas.

MSP Recovery NASDAQ:MSPR

$1.21 -0.05 (-3.97%)
As of 06/27/2025 03:59 PM Eastern

MSP Recovery, Inc. engages in the development of healthcare recoveries and data analytics software. It also focuses on the identification and recoveries of improper payments made by Medicare, Medicaid, and commercial insurance spaces using data and analytics. The company was founded by John H. Ruiz, Frank C. Quesada, and Diana Diaz on July 8, 2014 and is headquartered in Miami, FL.

Perrigo stock logo

Perrigo NYSE:PRGO

$26.55 -0.02 (-0.07%)
Closing price 06/27/2025 03:59 PM Eastern
Extended Trading
$26.50 -0.05 (-0.18%)
As of 06/27/2025 06:45 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Perrigo Company plc provides over-the-counter health and wellness solutions to enhance individual well-being in the United States, Europe, and internationally. It operates through Consumer Self-Care Americas and Consumer Self-Care International segments. The company develops, manufactures, markets, and distributes self-care consumer products, such as upper respiratory products, including cough suppressants, expectorants, and sinus and allergy relief; nutrition products consisting of infant formulas and nutritional beverages; digestive health products, including antacids, anti-diarrheal, and anti-heartburn; pain and sleep-aids products comprising pain relievers and fever reducers; and oral care products, which include toothbrushes, toothbrush replacement heads, floss, flossers, whitening products, and toothbrush covers. It also offers healthy lifestyle products, such as smoking cessation, well-being, and weight management products; skin care products consisting of dermatological care, scar management, lice treatment, and other products for various skin conditions; women's health products comprising feminine hygiene and contraceptives; vitamins, minerals, and supplements; rare diseases business; and other miscellaneous self-care products. The company sells its products under the Compeed, Dr. Fresh, Firefly, Good Sense, Good Start, Mederma, Nasonex, Plackers, Prevacid24HR, REACH, Rembrandt, Steripod, Opill, Solpadeine, Coldrex, Physiomer, NiQuitin, ACO, ellaOne, Compeed Stops, XLS, Arterin, Davitamon, Apiserum, Abtei, and Nicorette brands. It also offers contract manufacturing services. The company sells its products through retail drug, supermarket, and mass merchandise chains; e-commerce stores; wholesalers; pharmacies; drug and grocery retailers; and para-pharmacies. The company was formerly known as Perrigo Company and changed its name to Perrigo Company plc in December 2013. Perrigo Company plc was founded in 1887 and is headquartered in Dublin, Ireland.

Prometheus Biosciences stock logo

Prometheus Biosciences NASDAQ:RXDX

Prometheus Biosciences, Inc., a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of novel therapeutics for the treatment of inflammatory bowel diseases (IBD). Its lead product includes PRA023, a humanized IgG1 monoclonal antibody (mAb), which is in Phase IIa clinical trial for the treatment of ulcerative colitis and Crohn's disease, as well as systemic sclerosis-associated interstitial lung disease. The company also develops PR300, a G-protein coupled receptor modulator for IBD and potentially other immune-mediated diseases; PRA052, an anti-CD30L mAb for IBD; PR1100, an anti-cytokine receptor mAb for IBD and other immune-mediated diseases; and PR2100, an anti-inflammatory cytokine mAb for IBD, and inflammatory and fibrotic diseases. It has a diagnostics development and collaboration agreement with Takeda Pharmaceutical Company Limited; co-development and manufacturing agreement with Dr. Falk Pharma GmbH for PRA052; license agreement with Cedars-Sinai Medical Center; and strategic collaboration with Millennium Pharmaceuticals, Inc. The company was formerly known as Precision IBD, Inc. and changed its name to Prometheus Biosciences, Inc. in October 2019. Prometheus Biosciences, Inc. was incorporated in 2016 and is headquartered in San Diego, California. As of June 16, 2023, Prometheus Biosciences, Inc. operates as a subsidiary of Merck & Co., Inc.